Positive Outcomes from NTC's Phase II Mirakle Study
NTC, an international R&D-focused pharmaceutical company headquartered in Italy, has unveiled promising results from its Phase II MIRAKLE study. This multicenter, randomized, blinded-assessor study evaluates the efficacy and tolerability of NTC014, a combination of a quinolone antibiotic and an NSAID in eye drop form, for treating bacterial conjunctivitis in adults.
Assessment of Efficacy and Tolerability
Despite administering NTC014 at a lower dosage compared to traditional antibiotics—25% less than the antibiotic comparator—the results indicate that NTC014 exhibited non-inferiority in achieving microbiological eradication. It even demonstrated unexpected effectiveness against pathogens categorized as Intermediate or Resistant to the quinolone antibiotic. These outcomes are crucial in bolstering the potential of NTC014 as a new treatment option.
Insights from Leadership
Alessandro Colombo, Chief Scientific Officer of NTC, remarked, "These interim findings reaffirm that NTC014 is eligible to be a new treatment for bacterial conjunctivitis. Our commitment is to provide robust clinical evidence supporting the value of NTC014 in combating antibiotic resistance through the use of fewer antibiotics and a shorter treatment duration."
Addressing Unmet Medical Needs
Riccardo Carbucicchio, CEO of NTC, expressed optimism regarding the overall results from the MIRAKLE study. He highlighted that NTC014 is the first combination worldwide of an antibiotic and an NSAID, aiming to fulfill significant unmet medical needs in treating moderate to severe bacterial conjunctivitis—a common eye infection requiring effective intervention. NTC is dedicated to establishing commercial partnerships for this innovative asset globally by the end of 2025, with potential applications for surgical uses also under consideration.
The Ongoing Challenge of Conjunctivitis
Conjunctivitis, or pink eye, remains prevalent in various regions and poses economic and social challenges. Viral forms are the leading cause of infectious conjunctivitis; however, bacterial conjunctivitis ranks second, being the reason for 50% to 75% of cases in children. In this landscape, the efficacy of NTC014 could provide a much-needed solution.
NTC's Commitment and Achievements
NTC has gained recognition for its success in developing and launching the first combination of a quinolone and steroid for post-cataract surgery. This product has been licensed in almost 90 countries and is actively marketed across Europe, Asia, the Americas, and Africa.
About NTC
Headquartered in Milan, Italy, NTC is a pharmaceutical company with a commitment to research, development, registration, and commercialization of drugs and medical devices across multiple therapeutic areas including ophthalmology, pediatrics, gynecology, and gastroenterology. NTC prides itself on providing over 200 partners with high-quality standard pharmaceutical products.
Frequently Asked Questions
What is the NTC014 drug?
NTC014 is a combination of a quinolone antibiotic and an NSAID designed for treating bacterial conjunctivitis.
What were the results of the MIRAKLE study?
The study showed that NTC014 had non-inferiority in microbiological eradication compared to traditional antibiotics, even against resistant pathogens.
Who are the lead figures at NTC?
Alessandro Colombo serves as the Chief Scientific Officer, while Riccardo Carbucicchio is the CEO.
When is NTC expecting to finalize commercial partnerships?
NTC aims to finalize its commercial partnerships for NTC014 by the end of 2025.
What other areas does NTC focus on?
Besides ophthalmology, NTC develops products in pediatrics, gynecology, and gastroenterology, ensuring a diverse portfolio of pharmaceutical solutions.
